Axios reports: The trade deal between the U.S. and the European Union could hit the pharmaceutical industry with billions in new costs and ultimately drive up prices and limit access. Drugmakers have been heavily reliant on foreign countries’ manufacturing and raw materials, most of it duty-free. Those free-trade policies are on the way out as the U.S. prepares to impose …
Read More »